Tetrapyrroles and derivatives
Abcam IBM x , Non-specific cAMP and cGMP inhibitor, 1G
MW 222.24 Da, Purity >98%. Non-specific cAMP and cGMP inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam A 769662, AMP-activated protein kinase activator, 50MG
MW 360.4 Da, Purity >99%. Potent, reversible activator of AMP-activated protein kinase (AMPK) (EC₅₀ = 0.8 μM). Directly activates native rat AMPK by mimicking the effects of AMP - it activates AMPK both allosterically and by inhibiting dephosphorylation of AMPK. Shown to inhibit Na+-K+-ATPase at higher concentrations (IC₅₀ = 57 μM) . Inhibits differentiation of adipocytes.
The product is subject to the following: Abcam Restricted Use Statement
Abcam UDP-glucose, Highly P2Y14 agonist, 500MG
MW 610.27 Da. Highly potent, endogenous P2Y14 agonist (EC50 = 82 nM). Involved in modulation of gastric function. UDP also available (ab120383).
The product is subject to the following: Abcam Restricted Use Statement
Abcam E x endin-4 (E x enatide), GLP-1 receptor agonist, 1MG
MW 4187 Da, Purity >95%. Exendin-4 (Exenatide), GLP-1 receptor agonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam (R)-CPP, NMDA antagonist, 50MG
MW 252.2 Da. Highly potent, competitive NMDA antagonist; more active enantiomer of (RS)-CPP (ab120160). (Ki values are 0.04, 0.3, 0.6 and 2.0 μM at NR1/NR2A, NR1/NR2B, NR1/NR2C and NR1/NR2D, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Rebo x etine mesylate, Noradrenaline reuptake inhibitor, 50MG
MW 409.5 Da, Purity >99%. Potent, selective noradrenaline reuptake inhibitor, with high selectivity over dopamine and 5-HT transporters. Antidepressant in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 242084 hydrochloride, 5-HT2C antagonist, 50MG
MW 431.3 Da, Purity >98%. Potent, selective 5-HT2C antagonist (pKi values are 9 (5-HT2C), 7 (5-HT2B), 6.8 (5-HT2A), 6.4 (5-HT1A), 6.4 (5-HT1B), 6.4 (5-HT1D), 6 (5-HT1E), <6.1 (5-HT1F), <5.5 (5-HT4), 6 (5-HT6), 6.1 (5-HT7), 6.2 (D2), 6.2 (D3) and <5 (α1)). Blood-brain barrier permeable. Anxiolytic activity *in vivo*.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 203580, p38 MAPK inhibitor, 500UG
MW 377.4 Da, Purity >99%. SB 203580, p38 MAPK inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam E x endin-4 (E x enatide), GLP-1 receptor agonist, 500UG
MW 4187 Da, Purity >95%. Exendin-4 (Exenatide), GLP-1 receptor agonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Latrunculin A (LAT-A), Actin polymerization inhibitor, 500UG
MW 421.6 Da, Purity >95%. Actin polymerization inhibitor. Potent antiproliferative agent. Stabilizes monomeric G-actin. Shows greater potency than Latrunculin B (ab144291). Binds actin monomers near the nucleotide binding cleft with 1:1 stoichiometry. Inhibits growth of cancer cell lines (IC₅₀ values are 142, 142, 142, 166 and 95 nM for A549, H522-T1, HT-29, U-937 and MDA-MB-43 cells respectively). Shows convulsant effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Latrunculin A (LAT-A), Actin polymerization inhibitor, 100UG
MW 421.6 Da, Purity >95%. Actin polymerization inhibitor. Potent antiproliferative agent. Stabilizes monomeric G-actin. Shows greater potency than Latrunculin B (ab144291). Binds actin monomers near the nucleotide binding cleft with 1:1 stoichiometry. Inhibits growth of cancer cell lines (IC₅₀ values are 142, 142, 142, 166 and 95 nM for A549, H522-T1, HT-29, U-937 and MDA-MB-43 cells respectively). Shows convulsant effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam AT x -II, NaV channel activator, 100UG
MW 4941 Da, Purity >95%. ATX-II, NaV channel activator. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SCD1 Inhibitor, SCD1(stearoyl-CoA desaturase 1) inhibitor, 1MG
MW 387.9 Da, Purity >99%. Potent, selective SCD1 (stearoyl-CoA desaturase 1) inhibitor (IC₅₀ = 4.5 nM). Inhibits the conversion of saturated, long-chain fatty acyl-CoAs to monounsaturated, long-chain fatty acyl-CoAs in vitro, when heptadecanoic acid and palmitic acid are used as the substrate (IC₅₀ = 7.9 and 6.8 nM, respectively). Active in vivo. Orally bioavailable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam U-69593, kappa1-opioid receptor agonist, 5MG
MW 356.5 Da, Purity >99%. Potent, selective κ1-opioid receptor agonist (EC50 = 80-109 nM). Active *in vivo*. Antinociceptive.
The product is subject to the following: Abcam Restricted Use Statement
Abcam x anomeline o x alate, M1 muscarinic acetylcholine receptor agonist, 10MG
MW 371.5 Da, Purity >99%. Functionally preferring M₁ muscarinic acetylcholine receptor agonist (pKi values are 7.1 (M₁), 6.9 (M₂), 7.4 (M₃), 7.7 (M₄) and 7.4 (M₅)). Able to cross blood-brain barrier. Displays antipsychotic activity.
The product is subject to the following: Abcam Restricted Use Statement